Chung-Han Lee, MD, PhD | Authors


Discussing the Phase II Study of Lenvatinib/Pembrolizumab in Metastatic ccRCC

November 17, 2019

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma.